Eli Lilly and Company Stock Analysis - MarketRank™ See Top Rated MarketRank™ Stocks 99th Percentile Overall Score LLY MarketRank™: Eli Lilly and Company scoredhigher than 99% of companiesevaluated by MarketBeat, and ranked 14th out of 969 stocks in the medical sector. Scores are calcula...
misses expectations Eli Lilly 2012 profit forecast misses expectationsEli Lilly 2012 profit forecast misses expectationsTOM MURPHY
Eli Lilly and Company Stock Down 6.3 % The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. The company has a market capitalization of $804.90 billion, a PE ratio of 124.73, a price-to-earnings-growth ratio of 3.24 and a beta of 0.42...
The article reports on the increase in the fourth-quarter profit of Eli Lilly & Co. due to increased sales of drugs for mental illness and cancer. Unlike other pharmaceutical companies which face problems, the company's problem is expected to heat up in 2011 when its bestselling antipsychotic...
LLY Eli Lilly & Co.: LLY up +0.74% percent Today $LLY High is at 68.04 and the Low 67.56 with current volume of 418,916.
Feb 6 (Reuters) - Eli Lilly and Co cut its 2019 forecast for profit and revenue on Wednesday, citing the recent trial failure of its conditionally approved cancer drug Lartruvo and costs related to its pending acquisition of Loxo Oncology. Indianapolis-based Lilly is betting on new drugs and...
View that Strattera is a promising new, non-stimulant, first-line option for the treatment of ADHD; Forecast of$1.4 billion in Strattera worldwide sales in the year 2007; Predictions as to the market share that would be overtaken by Strattera; Description of side effects that can be caused ...